Lonza brings 2000-liter microbial facility on stream in Hopkinton

April 23,2009

Lonza announces the successful startup of its high-titer 2000-liter microbial manufacturing train in Hopkinton, MA (USA). This state-of-the-art production facility meets the high market demand for mid-scale capacity in microbial manufacturing and is backed by strong customer commitment.

The 2000 liter fermentation train is complemented by a highly flexible purification area capable of accommodating complex, high titer and throughput-optimized purification processes. In parallel Lonza also revamped the entire Hopkinton site infrastructure leading to an enhanced infrastructure reliability (utilities, electricity, waste streams) and increased operational efficiency while meeting cGMP requirements. A strong R&D organization is complementing the new manufacturing and infrastructure capabilities.

“We are happy to have finalized the build-out in Hopkinton on-time and in the record-breaking period of only nine months. Now we can offer our customers a state-of-the-art microbial manufacturing facility which allows for tailor-made multi-product operations. This 2000-liter mid-size facility is an ideal complement to our existing microbial capacities thus providing our customers the full range from small to large scale”, comments Dr. Jürg Burger, Head of Lonza Global Microbial Operation.


About Lonza

Lonza is one of the world's leading suppliers to the pharmaceutical, healthcare and life science industries. Its products and services span its customers’ needs from research to final product manufacture. Lonza is the global leader in the production and support of active pharmaceutical ingredients both chemically as well as biotechnologically. Biopharmaceuticals are one of the key growth drivers of the pharmaceutical and biotechnology industries. Lonza has strong capabilities in large and small molecules, peptides, amino acids and niche bioproducts which play an important role in the development of novel medicines and healthcare products. Lonza is a leader in cell-based research, endotoxin detection and cell therapy manufacturing. Lonza is also a leading provider of value chemical and biotech ingredients to the nutrition, hygiene, preservation, agro and personal care markets.

Lonza is headquartered in Basel, Switzerland and is listed on the SWX Swiss Exchange. In 2008, Lonza had sales of CHF 2.937 billion. Further information can be found at www.lonza.com.


For further information:

Head Corporate Communications
Michael Frizberg
Tel +41 61 316 8624
Fax +41 61 316 9624

Media Relations
Dominik Werner
Tel +41 61 316 8798
Fax +41 61 316 9798

Investor Relations
Alexandre Pasini
Tel +41 61 316 8835
Fax +41 61 316 9835

Browse All News